Mucosis Appoints Dr. Roberto Grimaldi As Chief Medical Officer
|| Print ||
|Tuesday, 27 April 2010 09:00 (UTC + 2)|
Groningen, the Netherlands, April 27, 2010 / b3c newswire / - Dutch vaccine development company MUCOSIS B.V. announced today that Dr. Roberto Grimaldi, MD was appointed Chief Medical Officer at Mucosis. Dr. Grimaldi is an accomplished executive and consultant to the vaccine industry who brings over 25 years of experience. As an expert on vaccine development he will lead the Mucosis development programs into clinical trials in the near future.
Before joining Mucosis as Chief Medical Officer, Dr. Grimaldi was Executive Vice President at Crucell N.V., responsible for product development and regulatory affairs. He also held responsible positions amongst others in Chiron Vaccines, Pharmacia & Upjohn, Sandoz and Farmitalia Carlo Erba. Dr. Grimaldi holds a degree in medicine and surgery from the University of Pavia (Italy), and is specialized in clinical pharmacology.
“Taking our vaccine programs into clinical development is key to Mucosis,” commented CEO Govert Schouten. “Our ability to attract such a highly-experienced person to lead these efforts gives us further confidence in a successful outcome of the various programs ongoing.”
Mucosis gives priority to taking its lead product FluGEM™ into clinical development. This innovative influenza vaccine can be administered by a simple spray in the nose. The FluGEM™ program is particularly directed at achieving better protection against seasonal influenza in vulnerable people, such as children and the elderly.
About Mucosis - www.mucosis.com
About Mimopath™ technology
For further information please contact: